Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
Bielack, S S
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 11 2019 - viii31-viii35 p. digital
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
1569-8041
10.1093/annonc/mdz382 doi
Drug Resistance, Neoplasm
Fibrosarcoma--drug therapy
Humans
Infant
Infant, Newborn
Male
Neoplasm Recurrence, Local--drug therapy
Oncogene Proteins, Fusion--genetics
Protein Kinase Inhibitors--therapeutic use
Pyrazoles--therapeutic use
Pyrimidines--therapeutic use
Salvage Therapy
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 11 2019 - viii31-viii35 p. digital
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
1569-8041
10.1093/annonc/mdz382 doi
Drug Resistance, Neoplasm
Fibrosarcoma--drug therapy
Humans
Infant
Infant, Newborn
Male
Neoplasm Recurrence, Local--drug therapy
Oncogene Proteins, Fusion--genetics
Protein Kinase Inhibitors--therapeutic use
Pyrazoles--therapeutic use
Pyrimidines--therapeutic use
Salvage Therapy